SANUWAVE Health Inc

Aktienanalyse zu SANUWAVE Health Inc (SNWV)

$4.675

+0.015 (+0.32%)Zum Schluss

Loading chart…
High
4.690
Open
4.650
VWAP
4.66
Vol
18.45K
Mkt Cap
Low
4.600
Amount
85.87K
EV/EBITDA, TTM
-30.20

Sanuwave Health, Inc. is an ultrasound and shock wave technology company. It is a provider of wound care products. It is focused on the research, development, and commercialization of its patented, non-invasive, and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. It applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, and aesthetic/cosmetic. Its two primary systems are UltraMIST and PACE. The UltraMIST system provides, through a fluid mist, low-frequency, non-contact, and pain free ultrasound energy deep inside the wound bed that promotes healing. The PACE systems use acoustic pressure shockwaves generated by the Company's Pulsed Acoustic Cellular Expression technology to converge at precise selected targets to produce short duration compression burst and are used in both wound and orthopedic applications under the brand names dermaPACE and others.

sanuwave.com

AI analysis of SANUWAVE Health Inc (SNWV)

hold

Sanuwave Health, Inc. (SNWV) is currently not a good buy due to its significant year-to-date decline of 83.82% and a low RSI of 34.916, indicating bearish momentum. While the company has shown some resilience with Q2 revenue exceeding revised guidance, the overall financial health remains concerning with a recent net income loss of $676,000 and a high debt-to-equity ratio of 688.05%.

Bewertungskennzahlen

The current forward P/E ratio for SANUWAVE Health Inc (SNWV) is 18.25, compared to its 5-year average forward P/E of 22.04.

Forward P/E

Fair
5Y Average P/E
22.04
Current P/E
18.25
Überbewertet
38.67
Unterbewertet
5.41

Forward EV/EBITDA

Undervalued
5Y Average EV/EBITDA
11.48
Current EV/EBITDA
-30.20
Überbewertet
33.09
Unterbewertet
-10.12

Forward P/S

Fair
5Y Average P/S
2.89
Current P/S
0.62
Überbewertet
5.19
Unterbewertet
0.59

Alphio AI Price Scenarios for SNWV

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%SNWV

$40.32

Szenariopreis

B

Base

Base · 50%SNWV

$36.11

Szenariopreis

B

Bear

Bear · 25%SNWV

$28.03

Szenariopreis

Event-Zeitleiste

2026-07-13 (ET)

17:00:00

Sanuwave Health Q2 Revenue Expected to Reach $9.6M-$9.8M

2026-05-12 (ET)

17:10:00

Sanuwave Reports Q1 Revenue of $9.6M

17:10:00

Sanuwave Health Maintains FY26 Revenue View of $51M-$55M

17:10:00

Sanuwave Health Sees Q2 Revenue of $11.1M-$11.6M

2026-04-17 (ET)

12:10:00

Iran's Strait of Hormuz Fully Open, Oil Prices Fall

News

SNWV FAQ — answered by Alphio AI

Sanuwave Health, Inc. is an ultrasound and shock wave technology company. It is a provider of wound care products. It is focused on the research, development, and commercialization of its patented, non-invasive, and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. It applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, and aesthetic/cosmetic. Its two primary systems are UltraMIST and PACE. The UltraMIST system provides, through a fluid mist, low-frequency, non-contact, and pain free ultrasound energy deep inside the wound bed that promotes healing. The PACE systems use acoustic pressure shockwaves generated by the Company's Pulsed Acoustic Cellular Expression technology to converge at precise selected targets to produce short duration compression burst and are used in both wound and orthopedic applications under the brand names dermaPACE and others. It operates in the Healthcare sector.

Sanuwave Health, Inc. (SNWV) is currently not a good buy due to its significant year-to-date decline of 83.82% and a low RSI of 34.916, indicating bearish momentum. While the company has shown some resilience with Q2 revenue exceeding revised guidance, the overall financial health remains concerning with a recent net income loss of $676,000 and a high debt-to-equity ratio of 688.05%.

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Kostenlos starten